Promising anti-leukemic activity of atorvastatin

Żołnierczyk,Jolanta  D.; Borowiak,Arleta; Hikisz,Paweł; Cebula-Obrzut,Barbara; Błoński,Jerzy  Z.; Smolewski,Piotr; Robak,Tadeusz; Kiliańska,Zofia  M.

doi:10.3892/or.2013.2301

Promising anti-leukemic activity of atorvastatin

Authors:
- Jolanta D. Żołnierczyk
- Arleta Borowiak
- Paweł Hikisz
- Barbara Cebula-Obrzut
- Jerzy Z. Błoński
- Piotr Smolewski
- Tadeusz Robak
- Zofia M. Kiliańska
View Affiliations

Affiliations: Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Łódź, 90-236 Łódź, Poland, Department of Experimental Hematology, Medical University of Łódź, 93-510 Łódź, Poland, Department of Hematology, Medical University of Łódź, 93-510 Łódź, Poland
Published online on: February 22, 2013 https://doi.org/10.3892/or.2013.2301
Pages: 2065-2071

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is a current need for novel therapeutic strategies for the treatment of chronic lymphocytic leukemia (CLL), a still incurable hematological cancer involving mainly deregulated apoptosis. The purpose of the present study was to determine ex vivo the effect of the synthetic statin, atorvastatin, a known cholesterol-lowering drug, on peripheral blood mononuclear cells obtained from CLL patients. Using flow cytometry, we investigated the viability and induction of apoptosis in leukemic cells exposed to statin by the Vybrant apoptosis assay kit #4, compared with untreated control cells. We also examined the expression levels of apoptosis-regulatory proteins (Mcl-1, Bcl-2 and Bax), as well as products of the expression/proteolysis of lamin B, poly(ADP-ribose) polymerase‑1 (PARP‑1) and p27Kip1 by western blot analysis. Moreover, the number of sub-G1 cells and DNA fragmentation in atorvastatin-treated leukemic cells were examined by flow cytometry and agarose gel electrophoresis, respectively. The obtained results indicated that CLL cells ex vivo were extremely sensitive to atorvastatin. The cytotoxic effect of this statin was caused by the induction of apoptosis in the leukemic cells. The induction of apoptosis in the drug-treated model cells was confirmed by the reduction or proteolysis of apoptotic markers, such as PARP-1, lamin B and p27Kip1, the increase in the number of sub-G1 cells and DNA ladder formation. During atorvastatin-triggered apoptosis, changes in the expression levels of mitochondrial outer membrane permeability regulatory proteins of the Bcl-2 family were also observed. Ex vivo promising data indicate the strong cytotoxic and pro-apoptotic potential of atorvastatin against leukemic cells, but not normal cells. The obtained data suggest that atorvastatin be considered as a therapeutic option for the treatment of CLL.

View Figures

View References

1	Eichhorst B, Dreyling M, Robak T, Montserrat E and Hallek M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 22(Suppl 6): vi50–vi54. 2011. View Article : Google Scholar : PubMed/NCBI
2	Brenner H, Gondos A and Pulte D: Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 111:4916–4921. 2008. View Article : Google Scholar : PubMed/NCBI
3	Kiliańska ZM and Rogalińska M: Potential new agents for chronic lymphocytic leukemia treatment. Anticancer Agents Med Chem. 10:666–682. 2010.
4	Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell’Aquila M and Kipps TJ: Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 96:2655–2663. 2000.PubMed/NCBI
5	Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F and Peschel C: Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood. 101:278–285. 2003. View Article : Google Scholar : PubMed/NCBI
6	Zhou Q and Liao JK: Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J. 74:818–826. 2010. View Article : Google Scholar : PubMed/NCBI
7	Roy M, Kung HJ and Ghosh PM: Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res. 1:542–561. 2011.PubMed/NCBI
8	Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H and Lishner M: Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol. 31:779–783. 2003. View Article : Google Scholar : PubMed/NCBI
9	Pahan K: Lipid-lowering drugs. Cell Mol Life Sci. 63:1165–1167. 2006. View Article : Google Scholar
10	Copajaa M, Venegasa D, Aránguiza P, et al: Simvastatin induces apoptosis by a Rho-dependent mechanism in cultured cardiac fibroblasts and myofibroblasts. Toxicol Appl Pharmacol. 255:57–64. 2011. View Article : Google Scholar : PubMed/NCBI
11	Wong WW, Dimitroulakos J, Minden MD and Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 16:508–519. 2002. View Article : Google Scholar : PubMed/NCBI
12	Chan KK, Oza AM and Siu LL: The statins as anticancer agents. Clin Cancer Res. 9:10–19. 2003.
13	Agarwal B, Halmos B, Feoktistov AS, et al: Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis. 23:521–528. 2002. View Article : Google Scholar : PubMed/NCBI
14	van de Donk NW, Schotte D, Kamphuis MM, van Marion AM, van Kessel B, Bloem AC and Lokhorst HM: Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clin Cancer Res. 9:5735–5748. 2003.PubMed/NCBI
15	Sleiffer S, van der Gaast A, Planting AS, Stoter G and Verweij J: The potential of statins as part of anti-cancer treatment. Eur J Cancer. 41:516–522. 2005. View Article : Google Scholar : PubMed/NCBI
16	Zhuang L, Kim J, Adam RM, Solomon KR and Freeman MR: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 115:959–968. 2005. View Article : Google Scholar : PubMed/NCBI
17	Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN and Pasternack BS: Clinical staging of chronic lymphocytic leukemia. Blood. 46:219–234. 1975.PubMed/NCBI
18	Kobylinska A, Bednarek J, Blonski JZ, Hanausek M, Walaszek Z, Robak T and Kilianska ZM: In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone. Oncol Rep. 16:1389–1395. 2006.
19	Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E and Gil J: In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood. 94:2836–2843. 1998.PubMed/NCBI
20	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275. 1951.PubMed/NCBI
21	Towbin H, Staechlin T and Gordon J: Electrophoretic transer of protein from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
22	Kajstura M, Halicka HD, Pryjma J and Darzynkiewicz Z: Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete ‘sub-G1’ peaks on DNA content histograms. Cytometry A. 71:125–131. 2007.PubMed/NCBI
23	Kim J-S, Pirnia F, Choi YH, et al: Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene. 19:6082–6090. 2000. View Article : Google Scholar : PubMed/NCBI
24	Podhorecka M, Halicka D, Klimek P, Kowal M, Chocholska S and Dmoszyńska A: Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 89:1115–1124. 2010. View Article : Google Scholar : PubMed/NCBI
25	Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F and Wang X: Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 17:1475–1486. 2003. View Article : Google Scholar : PubMed/NCBI
26	Johnston JB, Paul JT, Neufeld NJ, et al: Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk Lymphoma. 45:2017–2027. 2004. View Article : Google Scholar : PubMed/NCBI
27	Kobylinska A, Blonski JZ, Hanausek M, Walaszek Z, Robak T and Kilianska ZM: Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells. Oncol Rep. 11:699–705. 2004.
28	Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K and Sheridan DP: Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol. 75:22–33. 2004. View Article : Google Scholar : PubMed/NCBI
29	Muzio M, Apollonio B, Scielzo C, et al: Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 112:188–195. 2008. View Article : Google Scholar : PubMed/NCBI
30	Grzybowska-Izydorczyk O, Cebula B, Robak T and Smolewski P: Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer. 46:800–810. 2010. View Article : Google Scholar : PubMed/NCBI
31	Salman H, Bergman M, Djaldetti M and Bessler H: Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. Biomed Pharmacother. 62:41–45. 2008. View Article : Google Scholar : PubMed/NCBI
32	McConkey DJ: Calcium-dependent, interleukin 1-converting enzyme inhibitor-insensitive degradation of lamin B1 and DNA fragmentation in isolated thymocyte nuclei. J Biol Chem. 271:22398–22406. 1996.
33	Garnier P, Ying W and Swanson RA: Ischemic preconditioning by caspase cleavage of poly(ADP-ribose) polymerase-1. J Neurosci. 23:7967–7973. 2003.PubMed/NCBI
34	Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R and Ajchenbaum-Cymbalista F: Prognostic significance of the cell cycle inhibitor p27^Kip1 in chronic B-cell lymphocytic leukemia. Blood. 91:4694–4700. 1998.PubMed/NCBI
35	Eymin B, Sordet O, Droin N, et al: Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27^Kip1 mediates its anti-apoptotic activity. Oncogene. 18:4839–4847. 1999. View Article : Google Scholar : PubMed/NCBI
36	Zolnierczyk JD, Błoński JZ, Robak T, Kiliańska ZM and Wesierska-Gadek J: Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide. Ann NY Acad Sci. 1171:124–131. 2009. View Article : Google Scholar
37	Borner C: The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol. 39:615–647. 2003. View Article : Google Scholar : PubMed/NCBI
38	Skommer J, Wlodkowic D and Deptala A: Larger than life: mitochondria and the Bcl-2 family. Leuk Res. 31:277–286. 2007. View Article : Google Scholar : PubMed/NCBI
39	Osmak M: Statin and cancer: current and future prospects. Cancer Lett. 324:1–12. 2012. View Article : Google Scholar